Behavioral abnormalities in a genetic model of Duchenne myodystrophy in mice

Mutations in the Dmd gene encoding the membrane protein dystrophin are associated with the development of severe X-linked muscle diseases Duchenne and Becker myodystrophy. At the same time, along with the classic symptoms of striated muscles, dystrophin mutations can lead to a decrease in cognitive functions and behavioral abnormalities. Objective: conducting a pilot analysis of behavioral and cognitive characteristics in mice with a genetic defect that reproduces the phenotype of Duchenne myodystrophy. Materials and methods. To assess the features of motor functions and behavior, Dmd^Del8-34(n=13) and control animals of the wild type (n=12) were subjected to research in the tests "Load retention", "Rotarod", "Elevated plus maze" and "Object recognition". Results. It was found that mice carrying the Dmd^Del8-34 mutation are characterized by a decrease in motor functions, show signs of anxiety, and also show low exploratory activity. The detected features of the cognitive and emotional status are consistent with clinical observations indicating an increased risk of developing autism spectrum disorders and obsessive-compulsive disorder in patients with Dmd gene mutations. Thus, it was proved that from the 8^th week of life, mice of the Dmd^Del8-34 line show a decrease in performance in the Rotarod and Load Retention tests. Behavioral testing in the Elevated Plus Maze test revealed a decrease in time reaching a statistically significant difference compared to the wild-type control at week 12, and when assessing cognitive functions in the Object Recognition test, it was shown that Dmd^Del8-34mice show an increase in the discrimination index value, which is a sign of increased efficiency of hippocampal memory. Conclusion. The study made it possible to identify some behavioral anomalies in genetically modified mice carrying a large deletion of exons 8-34 of the Dmd gene encoding dystrophin.

1. Terry E.E., Zhang X., Hoffmann C., Hughes L.D., Lewis S.A., Li J., Wallace M.J., Riley L.A., et al. Transcriptional profiling reveals extraordinary diversity among skeletal muscle tissues. Elife. 2018;7:e34613. DOI: 10.7554/eLife.34613.

2. Frontera W.R., Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. 2015;96(3):183-195. DOI: 10.1007/s00223-014-9915-y.

3. Colson B.A., Gruber S.J., Thomas D.D. Structural dynamics of muscle protein phosphorylation. J Muscle Res Cell Motil. 2012;33(6):419-429. DOI: 10.1007/s10974-012-9317-6.

4. Gao Q.Q., McNally E.M. The Dystrophin Complex: Structure, Function, and Implications for Therapy.Compr Physiol. 2015;5(3):1223-1239. DOI: 10.1002/cphy.c140048.

5. Duan D., Goemans N., Takeda S., Mercuri E., Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. DOI: 10.1038/s41572-021-00248-3.

6. Dumont N.A., Wang Y.X., von Maltzahn J., Pasut A., Bentzinger C.F., Brun C.E., Rudnicki M.A. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21(12):1455-1463. DOI: 10.1038/nm.3990.

7. Chang N.C., Chevalier F.P., Rudnicki M.A. Satellite Cells in Muscular Dystrophy - Lost in Polarity. Trends Mol Med. 2016;22:479-496. DOI: 10.1016/j.molmed.2016.04.002.

8. Dumont N.A., Wang Y.X., von Maltzahn J., Pasut A., Bentzinger C.F., Brun C.E., Rudnicki M.A. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21: 1455-1463. DOI: 10.1038/nm.3990.

9. Muntoni F., Torelli S., Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2(12):731-740. DOI: 10.1016/s1474-4422(03)00585-4.

10. Rae M.G., O'Malley D. Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules. J Neurophysiol. 2016;116(3):1304-1315. DOI: 10.1152/jn.00248.2016.

11. Ferrero A., Rossi M. Cognitive profile and neuropsychiatric disorders in Becker muscular dystrophy: A systematic review of literature. Neurosci Biobehav Rev. 2022;137:104648. DOI: 10.1016/j.neubiorev.2022.104648.

12. Lidov H.G. Dystrophin in the nervous system. Brain Pathol. 1996;6(1):63-77. DOI: 10.1111/j.1750-3639.1996.tb00783.x.

13. Muntoni F., Torelli S., Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731-740. DOI: 10.1016/s1474-4422(03)00585-4.

14. Anderson J.L., Head S.I., Morley J.W. Duchenne muscular dystrophy and brain function M. Hedge, A. Ankala (Eds.), Muscular Dystrophy.Intech. 2012: 91-122. DOI: 10.5772/24928.

15. Gorecki D.C., Barnard E.A. Specific expression of G-dystrophin (Dp71) in the brain. NeuroReport. 1995;6:893-896. DOI: 10.1097/00001756-199504190-00017

16. Egorova T.V., Zotova E.D., Reshetov D.A., Polikarpova A.V., Vassilieva S.G., Vlodavets D.V., Gavrilov A.A., Ulianov S.V., et al. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. Dis Model Mech. 2019;12(4):dmm037655. DOI: 10.1242/dmm.037655.

17. Lim K.R.Q., Nguyen Q., Dzierlega K., Huang Y., Yokota T. CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy. Genes (Basel). 2020;11(3):342. DOI: 10.3390/genes11030342.

18. Gonzalez L.E., File S.E. A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J Neurosci. 1997;17(4):1505-1511. DOI: 10.1523/JNEUROSCI.17-04-01505.1997.

19. Leger M., Quiedeville A., Bouet V., Haelewyn B., Boulouard M., Schumann-Bard P., Freret T. Object recognition test in mice. Nat Protoc. 2013;8(12): 2531-2537. DOI: 10.1038/nprot.2013.155.

20. Deacon R.M. Measuring the strength of mice. J Vis Exp. 2013;(76):2610. DOI: 10.3791/2610.

21. Gao Q.Q., McNally E.M. The Dystrophin Complex: Structure, Function, and Implications for Therapy.Compr Physiol. 2015;5(3):1223-1239. DOI: 10.1002/cphy.c140048.

22. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., Kunkel L.M.Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50:509-517. DOI: 10.1016/0092-8674(87)90504-6.

23. Ahn A.H., Kunkel L.M. The structural and functional diversity of dystrophin. Nat Genet.,1993;3:283-291. DOI: 10.1038/ng0493-283.

24. Duchenne G.B.A. Reserches sur la paralysie musculaire pseudeohypertrofique, ou paralysie myo-sclerosique. Arch Gen Med. 1868;11:5-25, 179-209,305-121, 421-143,552-188

25. Cotton S., Voudouris N.J., Greenwood K.M.Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol. 2001;43:497-501. DOI: 10.1017/s0012162201000913.

26. Hendriksen J.G., Vles J.S. Are males with Duchenne muscular dystrophy at risk for reading disabilities? Pediatr Neurol. 2006;34:296-300. DOI: 10.1016/j.pediatrneurol.2005.08.029.

27. Hendriksen J.G., Vles J.S. Neuropsychiatric disorders in males with Duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol. 2008;23:477-481. DOI: 10.1177/0883073807309775.

28. Snow W.M., Anderson J.E., Jakobson L.S. Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci Biobehav Rev. 2013;37:743-752. DOI: 10.1016/j.neubiorev.2013.03.016.

29. Etemadifar M., Molaei S. Epilepsy in boys with Duchenne muscular dystrophy. J Res Med Sci. 2004;3:116-119.

30. Goodwin F., Muntoni F., Dubowitz V. Epilepsy in Duchenne and Becker muscular dystrophies. Eur J Paediatr Neurol: Off J Eur Paediatr Neurol Soc. 1997;1:115-119. DOI: 10.1016/s1090-3798(97)80042-6

31. Pane M., Messina S., Bruno C., D'Amico A., Villanova M., Brancalion B., Sivo S., Bianco F., et al. Duchenne muscular dystrophy and epilepsy. Neuromuscul Disord. 2013;23(4):313-315. DOI: 10.1016/j.nmd.2013.01.011.

32. Lee A.J., Buckingham E.T., Kauer A.J., Mathews K.D. Descriptive Phenotype of Obsessive Compulsive Symptoms in Males With Duchenne Muscular Dystrophy. J Child Neurol. 2018;33(9):572-579. DOI: 10.1177/0883073818774439.

33. de Brouwer A.P., Nabuurs S.B., Verhaart I.E., Oudakker A.R., Hordijk R., Yntema H.G., Hordijk-Hos J.M., Voesenek K., et al. A 3-base pair deletion, c.9711_9713del, in DMD results in intellectual disability without muscular dystrophy. Eur J Hum Genet. 2014;22(4):480-485. DOI: 10.1038/ejhg.2013.169.

34. Chamberlain J.S., Pearlman J.A., Muzny D.M., Gibbs R.A., Ranier J.E., Caskey C.T., Reeves A.A. Expression of the murine Duchenne muscular dystrophy gene in muscle and brain. Science. 1988;239(4846):1416-1418. DOI: 10.1126/science.3347839.

35. Lidov H.G., Byers T.J., Kunkel L.M. The distribution of dystrophin in the murine central nervous system: an immunocytochemical study. Neuroscience. 1993;54:167-187. DOI: 10.1016/0306-4522(93)90392-s.

36. Blake D.J., Kröger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle? Trends Neurosci. 2000;23:92-99. DOI: 10.1016/s0166-2236(99)01510-6.

37. Graciotti L., Minelli A., Minciacchi D., Procopio A., Fulgenzi G. GABAergic miniature spontaneous activity is increased in the CA1 hippocampal region of dystrophic mdx mice Neuromuscul Disord. 2008;18:220-226. DOI: 10.1016/j.nmd.2007.11.009.

38. Lidov H.G., Selig S., Kunkel L.M. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 1995;4:329-335. DOI: 10.1093/hmg/4.3.329.

39. Anderson J.L., Head S.I., Rae C., Morley J.W. Brain function in Duchenne muscular dystrophy. Brain. 2002;125:4-13. DOI: 10.1093/brain/awf012.

40. Cyrulnik S.E., Hinton V.J. Duchenne muscular dystrophy: a cerebellar disorder? Neurosci Biobehav Rev. 2008:32:486-496. DOI: 10.1016/j.neubiorev.2007.09.001.

41. Lidov H.G. Dystrophin in the nervous system. Brain Pathol. 1996;6:63-77. DOI: 10.1111/j.1750-3639.1996.tb00783.x.

42. Brünig I., Suter A., Knuesel I., Lüscher B., Fritschy J.M. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin. J Neurosci: Off J Soc Neurosci. 2002;22:4805-4813. DOI: 10.1523/JNEUROSCI.22-12-04805.2002.

43. Kueh S.L., Head S.I., Morley J.W. GABA(A) receptor expression and inhibitory post-synaptic currents in cerebellar Purkinje cells in dystrophin-deficient mdx mice. Clin Exp Pharmacol Physiol. 2008;35:207-210. DOI: 10.1111/j.1440-1681.2007.04816.x.

44. Vaillend C., Billard J.M. Facilitated CA1 hippocampal synaptic plasticity in dystrophin-deficient mice: role for GABAA receptors? Hippocampus. 2002;12: 713-717. DOI: 10.1002/hipo.10068.

45. Craig A.M., Kang Y. Neurexin-neuroligin signaling in synapse development. Curr Opin Neurobiol. 2007;17:43-52. DOI: 10.1016/j.conb.2007.01.011.

46. Albrecht D.E., Froehner S.C. Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. Neurosignals. 2002;11:123-129. DOI: 10.1159/000065053.